NCT04644809 is a Phase 1 clinical trial of LY3561774 in Dyslipidemias, sponsored by Eli Lilly and Company.

Who is sponsoring NCT04644809?

NCT04644809 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT04644809?

Interventions in NCT04644809: LY3561774, Placebo.

What condition does NCT04644809 study?

NCT04644809 studies Dyslipidemias.

Is NCT04644809 still recruiting?

NCT04644809 is currently completed. Last updated 10 August 2022.

Last reviewed 2022-08-10 · How we verify

NCT04644809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3561774 in Participants With Dyslipidemia

Completed Phase 1 Last updated 10 August 2022

What this trial tests

Phase 1 trial testing LY3561774 in Dyslipidemias in 74 participants. Completed in 17 May 2022.

Timeline

30 November 2020

Primary endpoint
17 May 2022

17 May 2022

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	basic science
Enrollment	74
Start date	30 November 2020
Primary completion	17 May 2022
Estimated completion	17 May 2022
Sites	5 locations across United States

Drugs / interventions tested

LY3561774 — full drug profile →
Placebo

Conditions studied

Dyslipidemias — all drugs for Dyslipidemias →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 65, any sex, with Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of LY3561774

Trials testing the same drug.

NCT05256654 — A Study of LY3561774 in Participants With Mixed Dyslipidemia · Phase 2 · completed

Other recruiting trials for Dyslipidemias

Currently open trials in the same condition.

NCT07308314 — Taining Golden Lake Comprehensive Chronic Disease Management Initiative · recruiting
NCT06526273 — PILI 'Āina Household · NA · recruiting
NCT06797401 — Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia · Phase 2 · recruiting
NCT06380322 — Military Health and Nutrition Examination Study · recruiting
NCT06183307 — Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia · NA · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04644809 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 10 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04644809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing